Spain-based drug company Grifols disclosed in a recent securities filing that it is conducting an internal investigation across numerous countries in Europe and the Middle East into potential violations of the Foreign Corrupt Practices Act.
The investigation, which is being carried out by an external legal adviser, focuses on sales to certain Central and Eastern European countries, specifically Belarus and Russia. Trading practices in Brazil, China, Georgia, Iran, and Turkey are also being investigated, in addition to other countries “considered necessary,” the filing stated.
